The rational design and development of anti-venom drugs for snakebites based on the endogenous inhibitors from Japanese Viper

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K18880
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Biological pharmacy
• Research Institution: Fukuoka University
• Principal Investigator: Shioi Narumi (青木成留実) 福岡大学, 理学部, 助教 (50510187)
• Research Collaborator: Maenaka Katsumi ; Kurahara Lin Hai ; Hu Yaopeng ; Hiraishi Keizo ; Hirano Toru
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: ヘビ毒タンパク質 / ヘビ血清タンパク質 / 毒素阻害剤 / イオンチャネルブロッカー

Outline of Final Research Achievements

According to WHO report is estimated 5.4 million people are bitten each year. Snakebite is a serious problem as a neglected public health issue in the world. A crude venom contains various proteins induced various effects in their prey or their human victim.
On the other hand, venomous snakes have endogenous proteins to neutralize the toxicity of their venom components. We identified new class of endogenous inhibitors from Protobothrops flavoviridis serum.
In this study, we investigated of potential utility of SSPs in therapeutic drug for snakebites as follows; (1) we have identified target ion channels of ion channel blockers of Japanese Viper and revealed that venom snake serum protein inhibits the toxin's physiological activity. (2) Peptides synthesis of the toxin binding domains of the inhibitory proteins were carried out using a phage display method and chemical synthesis method. (3) We identified binding proteins from several snake crude venoms using by snake blood components.

Free Research Field

生化学